表纸
市场调查报告书

药品价格和医疗费用报销:全球市场

Pharmaceutical Pricing and Reimbursement: Global Markets

出版商 BCC Research 商品编码 948545
出版日期 内容资讯 英文 164 Pages
订单完成后即时交付
价格
药品价格和医疗费用报销:全球市场 Pharmaceutical Pricing and Reimbursement: Global Markets
出版日期: 2020年07月09日内容资讯: 英文 164 Pages
简介

预计到2024年,全球制药市场将从2019年的1.580万亿美元增至1.52万亿美元,预计2019年至2024年的复合年增长率为7.5%。

本报告调查了过去10年中全球药品市场的药品价格和医疗费用报销,全球药品市场中医疗体系的改革和法规及其对行业并购和风险资本家投资的影响。美国和欧洲的分析,药品定价和报销政策和程序,以及有关如何投资仿制药,生物仿制药,非处方药(OTC),小分子和生物制剂的评论。

第1章简介

  • 研究目的
  • 调查原因
  • 报告范围
  • 信息来源
  • 调查方法
  • 区域细分
  • 分析师职业
  • BCC海关调查
  • BCC研究相关报告

第2章摘要摘要

第3章全球医疗保健支出,法律和定价机制

  • 全球医疗费用
  • COVID之前的预测
  • COVID之后的预测
  • 对COVID-19紧急治疗的反应
  • 扩展低成本数字服务
  • COVID-19的研发资金
  • 药品支出
  • 北美
  • 欧洲
  • 日本
  • 金砖四国
  • COVID-19对2020年第一季度药品销售的影响
  • 并购(并购)
  • 2019年之前的并购活动
  • 2019并购活动
  • 2020年第一季度的并购活动
  • 医疗改革
  • 法国
  • 德国
  • 意大利
  • 西班牙
  • 英国
  • 美国
  • 药品监管
  • 法国
  • 德国
  • 意大利
  • 西班牙
  • 英国
  • 美国
  • COVID-19对医疗保健的急性影响
  • 法国
  • 德国
  • 意大利
  • 西班牙
  • 英国
  • 美国

第4章定价策略

  • 简介
  • 药品成本上涨的主要原因
  • 用更新,更昂贵的药物代替旧的低成本药物
  • 增加使用药物
  • 无法治愈的疾病新药
  • 现有药品的价格上涨
  • 药品定价策略
  • 外部价格参考
  • 内部参考价
  • 处方药价格
  • 英国
  • 美国
  • 非处方药(OTC)价格
  • 欧洲
  • 英国
  • 美国
  • 仿制药价格
  • 英国
  • 美国
  • 稀有药品价格
  • 基于价值的定价
  • 公开招标和采购
  • 框架协议方法/框架协议

第5章医疗费用报销策略

  • 药品兑换
  • 批准医疗报销
  • 医疗费用报销程序
  • 欧洲
  • 英国
  • 美国
  • 报销医院医疗费用
  • 欧洲
  • 英国
  • 美国
  • 患者访问方案
  • 财务基础计划
  • 基于结果的方案
  • 及早获得毒品计划
  • 欧洲
  • 英国
  • 美国
  • 处方清单
  • 欧洲
  • 英国
  • 美国
  • 医疗技术评估(HTA)
  • 欧洲
  • 英国
  • 美国
  • 成果研究的价值(HEOR)
  • HEOR十大趋势

第6章未来

  • 扩大采用基于价值的定价方案
  • 增加对细胞/基因治疗的投资
  • 创新的付款方式
  • 英国脱欧更加清晰
  • 关于药品价格的政治争议
  • 对COVID-19的长期反应尚不清楚

第7章参考

目录
Product Code: PHM189A

Highlights:

The global pharmaceuticals market was valued at $1,058 billion in 2019 and should reach $1,520 billion by 2024 with a compound annual growth rate (CAGR) of 7.5% from 2019 to 2024.

Report Scope:

This new report on pricing and reimbursement in a global market provides a brief overview on the pharmaceutical markets, healthcare reforms and regulations across the globe over the last decade and how this has impacted mergers and acquisitions and venture capitalist investment in the sector. It reviews pricing and reimbursement policies and processes in the U.S. and Europe and the ways in which pharmaceutical investment in generics, biosimilars, over the counter (OTC), small molecule and biological agents; and the shift toward more innovative medicines such as cell and gene therapies may change future treatment paradigms and future pricing and reimbursement policies.

Report Includes:

  • An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures
  • Analyses of the global market trends, with data corresponding to market size for 2014-2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry
  • Case studies of different price and reimbursement strategies for prescription drugs, orphan drugs, generics, over-the-counter products, and value-based pricing
  • Discussion on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall healthcare marketplace
  • Insight into the greater adoption of value-based pricing schemes, with emphasis on the innovative payment models, increased investment in cell and gene therapies, and long-term response to COVID-19

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Global Healthcare Expenditures, Legislation and Pricing Mechanisms

  • Global Healthcare Costs
  • Forecasts Pre-COVID
  • Forecasts Post-COVID
  • Acute Healthcare Response to COVID-19
  • Expansion of Low-Cost Digital Services
  • Funding for COVID-19 Research and Development
  • Drug Expenditures
  • North America
  • Europe
  • Japan
  • BRIC Economies
  • Impact of COVID-19 on Pharmaceutical Sales in Q1 2020
  • Mergers and Acquisitions (M&A)
  • M&A Activity Pre-2019
  • M&A Activity in 2019
  • M&A Activity in Q1 2020
  • Healthcare Reforms
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Pharmaceutical Regulation
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Acute Impact of COVID-19 on Healthcare
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States

Chapter 4 Pricing Strategies

  • Introduction
  • Primary Reasons for the Rise in the Cost of Pharmaceuticals
  • Replacement of Older, Lower-Cost Drugs by Newer, Higher Priced Drugs
  • Increased Use of Drugs
  • New Drugs for Diseases for Which No Treatment Was Previously Available
  • Increases in the Prices of Existing Medicines
  • Pharmaceutical Pricing Strategies
  • External Price Referencing
  • Internal Referencing Pricing
  • Prescription Drug Pricing
  • United Kingdom
  • United States
  • Over-the-Counter (OTC) Drug Pricing
  • Europe
  • United Kingdom
  • United States
  • Generic Drug Pricing
  • United Kingdom
  • United States
  • Orphan Drug Pricing
  • Value-Based Pricing
  • Open Tender Invitations and Procurement
  • Framework Agreements

Chapter 5 Reimbursement Strategies

  • Pharmaceutical Reimbursement
  • Admission to Reimbursement
  • Reimbursement Procedure
  • Europe
  • United Kingdom
  • United States
  • Hospital Reimbursement
  • Europe
  • United Kingdom
  • United States
  • Patient Access Schemes
  • Financially Based Schemes
  • Outcome-Based Schemes
  • Early Access to Medicines Schemes
  • Europe
  • United Kingdom
  • United States
  • Formulary Lists
  • Europe
  • United Kingdom
  • United States
  • Health Technology Assessments (HTA)
  • Europe
  • United Kingdom
  • United States
  • The Value of Health Economics and Outcome Research (HEOR)
  • Top 10 HEOR Trends

Chapter 6 The Future

  • Greater Adoption of Value-Based Pricing Schemes
  • Increased Investment in Cell and Gene Therapies
  • Innovative Payment Models
  • Greater Clarity on Brexit
  • Political Wrangling Over Drug Prices
  • Long-term Response to COVID-19 Undefined

Chapter 7 References

List of Tables

  • Table 1 : Major Market Drivers of Global Healthcare Expenditures
  • Table 2 : Total Healthcare Expenditure in G20 Economies, 2018
  • Table 3 : Inpatient Care Average Length of Stay in All Hospitals, 2014
  • Table 4 : Steps Implemented to Access Diagnostics and Treatment Following the COVID-19 Pandemic
  • Table 5 : Steps Implemented to Boost and Optimize Healthcare Capacity
  • Table 6 : COVID-19 Vaccines under Development
  • Table 7 : COVID-19 Treatments under Development
  • Table 8 : Major Mergers and Acquisitions in the Global Pharmaceutical Market, 2019
  • Table 9 : Major M&A Deals in the Global Pharmaceutical Market, Q1 2020
  • Table 10 : Allowed Growth Rates, 2014-2018
  • Table 11 : Net Revenues Retained in the U.S. Pharmaceutical Market, by Type of Prescription Drug Participant, 2016
  • Table 12 : Pricing of Medicines in Europe
  • Table 13 : Using Market Forces to Price Generics in the U.K.
  • Table 14 : Pricing Policies for Biosimilars in Europe, as of April 2017
  • Table 15 : National Authorities in Charge of Market Authorization, Pricing and Reimbursement in the EU5 Countries
  • Table 16 : Federally Funded Health Insurance Programs in the U.S.
  • Table 17 : An Overview of Early Access Schemes
  • Table 18 : Example of a Five-Tier Formulary System in the U.S.
  • Table 19 : Acronyms Used in the Global Pharmaceutical Pricing and Reimbursement Market

List of Figures

  • Figure 1 : Projected Annual Growth in Global Healthcare Spending, 2020
  • Figure 2 : Global GDP Growth Forecast Comparison, February 2020 vs. May 2020
  • Figure 3 : Overview of Coronavirus Impact Index, by Industry
  • Figure 4 : Potential Initial Impact of Partial or Complete Shutdowns on Activity in the G7 Economies
  • Figure 5 : Schematic Diagram of Global Healthcare Spend to Increase, 2020
  • Figure 6 : Trends in Global Pharmaceuticals Sales, by Market Segment, 2018-2024
  • Figure 7 : Projected Annual Growth Forecast in Global Pharmaceutical Market, by Region Group, 2018-2022
  • Figure 8 : Market Shares of Generic Medicine Sales in Selected European Countries, as of 2016
  • Figure 9 : Cumulative Pharmaceutical M&A Spending Comparison, 2019 vs. 2018
  • Figure 10 : Healthcare Reforms in Germany
  • Figure 11 : Worldwide Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 12 : Regional Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 13 : European Countries Where External Reference Pricing is Used
  • Figure 14 : Overview of Countries that Refer to the U.K.
  • Figure 15 : European Countries Where Internal Reference Pricing is Used
  • Figure 16 : NHS Spending on Prescription Pharmaceuticals, 2010-2018
  • Figure 17 : Pharmaceutical Pricing Process in the U.S.
  • Figure 18 : Countries Using Generic Prices in Europe
  • Figure 19 : Share of Generic Drug Sales (by Value and Volume) Across the OECD Nations, 2014
  • Figure 20 : Comparing Prices of Biosimilars and Branded Products
  • Figure 21 : U.S., EU and Japan Orphan Designations per Year and Cumulative, 1983-2016
  • Figure 22 : Top 100 Orphan Drug Costs per Patient per Year in the U.S., 2012-2016
  • Figure 23 : Value-Based Pricing Process in the U.K.
  • Figure 24 : Overview of Pharmaceutical Tendering Process
  • Figure 25 : Overview of the Application of Reimbursement Schemes in Europe
  • Figure 26 : Organization of the U.S. Healthcare System
  • Figure 27 : U.S. Healthcare Expenditures as a Share of GDP, by Source of Funds, 1987-2018
  • Figure 28 : Organization of the Healthcare System in England
  • Figure 29 : Evolution of PAS England, 2007-2015
  • Figure 30 : PAS Approval Process (Simplified Version)
  • Figure 31 : Pathways for Accessing an Orphan Therapy in the EU
  • Figure 32 : Three-Stage EAMS Process in the U.K.
  • Figure 33 : Types of Reimbursement Lists Used in the Outpatient Sector Europe
  • Figure 34 : Process of Identifying if an Item Can be Prescribed on the NHS
  • Figure 35 : Two Simplified Examples of HTA Utilization in Europe
  • Figure 36 : Tools and Disciplines Involved HEOR Analysis
  • Figure 37 : Elements of Value-Based Pricing
  • Figure 38 : Global Cell and Gene Therapy Market, 2018 vs. 2024
  • Figure 39 : Innovative Payment Models for Cell and Gene Therapies
  • Figure 40 : Four Waves of COVID-19 on Healthcare